Navigation Links
MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease

dard of care."

The Phase 3 study was designed to compare the safety and efficacy of motavizumab with that of Synagis, which was first launched by MedImmune in 1998, in reducing serious RSV disease in high-risk infants in the inpatient and outpatient settings. As defined in the study, infants who are at high risk for RSV include those who were born at 35 weeks gestation or less as well as those who have chronic lung disease (CLD) due to being born prematurely. The primary endpoint was to assess the incidence of RSV hospitalizations with motavizumab compared to Synagis. Motavizumab met the primary endpoint, demonstrating non-inferiority to Synagis with 26 percent fewer RSV hospitalizations in motavizumab-treated infants. The overall RSV attack rate was low in both treatment groups: 1.4 percent for infants who received motavizumab, compared with 1.9 percent for those who received Synagis [RR: 0.740, 95 percent CI: (0.503, 1.083)]. The p-value for non-inferiority was p<0.01, demonstrating a significant finding.

Analysis of the data also showed that motavizumab reduced the incidence of RSV-specific medically attended outpatient LRIs (the study's RSV-related secondary endpoint) by approximately 50 percent compared with Synagis. The overall RSV-specific medically attended LRI rate was 2.0 percent for infants who received motavizumab compared with 3.9 percent for those who received Synagis (p<0.01). There were no significant differences in other non-RSV- specific endpoints.

"I am very pleased with the study results for motavizumab," said Xavier Carbonell, M.D., Ph.D., lead study author, chairman of neonatology, Barcelona Hospital Clinic, and vice president, Spanish Neonatal Society. "As a practicing neonatologist, I look forward to the potential to use this next- generation antibody to help reduce RSV-related hospitalizations and LRIs in the outpatient setting."

Data from this trial demonstrate that both study drugs were well tolerated. The incid
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
7. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
8. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
9. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:10/25/2014)... HOUSTON , Oct. 24, 2014   Metanome, ... of comprehensive metagenomic services and data analysis, was the ... Mass ) Phase I/II clinical trial of SER ... with recurrent Clostridium difficile infections (CDI). ... of Seres Health,s R&D and clinical programs. Such genomic ...
(Date:10/25/2014)... , Oct. 24, 2014 Best ... Medical Affairs leaders with a forum for sharing ... consortium has developed a mechanism for creating and ... leaders discuss key findings from the Medical Affairs ... completed the analysis for the first roundtable of ...
(Date:10/22/2014)... , Oct. 22, 2014  Rescheduling of hydrocodone ... in the pain market, according to a new ... a firm providing market research and consultation exclusively ... Photo - http://photos.prnewswire.com/prnh/20141021/153440 ... for hydrocodone combination products from Schedule III to ...
Breaking Medicine Technology:Metanome Selected as Metagenomics Provider for Seres Health Clinical Trial 2Strong Participation in Best Practices' Medical Affairs Consortium Survey 2Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3
(Date:10/25/2014)... Reinberg HealthDay Reporter FRIDAY, ... common cold sores -- herpes simplex -- might increase the ... In fact, being a carrier of certain antibodies to ... researchers found. "The identification of a treatable cause ... breakthrough," said lead researcher Dr. Hugo Lovheim, an associate professor ...
(Date:10/25/2014)... News) -- A large influx of international aid is ... tens of thousands of deaths from the widening Ebola ... Using a specially designed mathematical model, the researchers ... just one densely populated county of hard-hit Liberia -- ... The researchers said that if international aid isn,t ...
(Date:10/25/2014)... News) -- October,s shorter, darker days can trigger a ... to an expert. People affected by seasonal ... lack motivation and even have trouble getting out of ... said Dr. Angelos Halaris, a professor in the department ... Stitch School of Medicine. "Seasonal affective disorder should ...
(Date:10/22/2014)... Austin, TX (PRWEB) October 22, 2014 ... Criminal Minds featuring skin diseases both fictional ... Foundation (CEHMDF), a nonprofit organization committed to advocacy ... wondering if CBS will take the opportunity to impart ... disease. , There are many misconceptions about ...
(Date:10/22/2014)... For Dr. Iris Hunter, a job is more ... of her life’s mission. Her extensive experience in the nonprofit ... FirstLight HomeCare, make it clear that Hunter’s mission is to ... work makes a difference in the lives of others,” Hunter ... much research, I felt ready to start on this journey ...
Breaking Medicine News(10 mins):Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2
... dropped most pounds went off diabetes meds and ... News) -- Weight loss plays a major role in ... Duke University Medical Center researchers. , Previous studies ... how food is sent from the stomach to the ...
... Help, a patient safety program launched more than ... of UPMC, has significantly improved communication between caregivers ... a review of the program has found. , ... the nation working with the Josie King Foundation ...
... and development collaboration between leading Australian Institutions, the ... University of Melbourne and Bio-Link Partners Ltd., has ... 2008 New Therapy Grant winners. This prestigious research ... is focussed on development and commercialisation of small ...
... Affirms Industry Dominance, DALLAS, June 18 ... the leader in hosted services for email ... processed a record 20,million prescription transactions through ... accredited center. Over 3,200 active,prescribers across eight ...
... to get up from a ... fall safely, ... AEX: PHI) today announced the launch of the website, http://www.LearnNotToFall.com in ... makers of the popular personal,emergency response system, the site features four sections, ...
... today, released a report ,Australian Dementia Research, that recommends ... $36 million in response to the growing economic and ... Prepared by the Dementia Collaborative Research Centre at the ... over the last six years in dementia research was ...
Cached Medicine News:Health News:Weight Loss After Gastric Bypass Is Key to Easing Diabetes 2Health News:Study finds Children's Hospital patient safety program improves caregiver/family communications 2Health News:Dynamin drug discovery team win prestigious international epilepsy grant 2Health News:Dynamin drug discovery team win prestigious international epilepsy grant 3Health News:Zix Corporation Processes More Than 20 Million Electronic Prescriptions 2Health News:Zix Corporation Processes More Than 20 Million Electronic Prescriptions 3Health News:Philips Web Site Offers Seniors and Caregivers Tips and Techniques for Preventing Falls 2Health News:Philips Web Site Offers Seniors and Caregivers Tips and Techniques for Preventing Falls 3Health News:Invest in a future without dementia 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: